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"It's far more important to know what person the disease has than what disease the person 
has" – Hippocrates (c. 460 BC – c. 370 BC) 
 
There is a pressing need to personalise cardiovascular disease prevention and nowhere 
more so than in treating hypertension[1]. Hypertension should no longer be treated as an 
individual disease, but in the context of a patient’s total cardiovascular risk; new guidelines 
[2] may lead to half of the American population being considered for drug therapy to lower 
blood pressure, but if there were ways to identify those who would benefit; this number 
might be reduced greatly with considerable cost savings. One approach would be to look for 
evidence of target organ damage and use this as additional reason for starting treatment. 
The prognostic impact of regressing vascular structural alterations for a number of 
cardiovascular and metabolic diseases is a clinical priority.  Understanding the significance of 
the microcirculation and how even small architectural changes can impact on normal 
physiological processes underlies the importance of this system as a potential tool to add to 
making clinical judgements. The past 25 years of research in the field has identified some 
key principles; (i) the significance of the microcirculation on the regulation of blood pressure 
[3, 4] (ii) that these vessels undergo active and adaptive remodelling to long term 
haemodynamic changes [5] (iii) remodelling of resistance arteries can be categorised as 
inward eutrophic (rearrangement of otherwise normal material around a narrowed lumen) 
or inward hypertrophic remodelling (vascular smooth muscle cell hypertrophy or 
hyperplasia) [6] (iv) the increase in the media-to-lumen ratio linked with remodelling is a 
powerful predictor of cardiovascular events [7].  
Despite consistent research over the past 25 years seeking to understand the mechanisms 
by which remodelling occurs, very few contribute to the translational power that is gained in 
understanding how they contribute to vascular normality. Using a disease-centred tool in 
which individuals have one single condition is not appropriate for the array of cardiovascular 
diseases of which patients are at risk if indeed the current understanding is correct. 
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However, defining normality is a problem; non-modifiable risk factors including sex, age and 
ethnicity change what is ‘normal’, yet very few studies factor this in to their prognostic 
calculations. This shift in thought is supported by a recent study by Puato and colleagues 
which highlights that accurate phenotyping of the cardiovascular risk profile of each patient, 
alongside a patient-tailored pharmacological approach is the most effective strategy to limit 
vascular damage and associated cardiovascular risk [8]. Therefore it is perhaps unsurprising 
that the current day research has experienced a move to ‘personalise’ prognostic tools 
based on remodelling measures to enhance their usability in the clinical setting, thus 
delivering more patient-centred care.  
The research from this group has made significant contributions in terms of our overall 
understanding of how vascular remodelling is linked to hypertension. In this issue of the 
Journal, Bruno and colleagues seek to establish age- and sex-specific reference values for 
media to lumen ratios in small arteries [1]. In a multi-centre study, Bruno and colleagues 
have recruited almost 300 patients, 91 of whom were healthy, and have presented the 
largest cohort of data collected though myography assessment. Using resistance arteries 
found in abdominal or gluteal biopsies, the authors have performed statistical analysis to 
assess media to lumen ratios and have calculated age and sex-specific reference intervals 
for healthy individuals. They then examined whether these were affected by significant 
cardiovascular risk factors including BMI, fasting blood glucose, smoking status, systolic 
blood pressure and total cholesterol. From these data, Bruno et al. propose that these 
values will be helpful for the further investigation of cardiovascular risk factors in 
microvascular damage and any associated organ damage, as well as allowing for the 
effectiveness of treatments to be ascertained. As well as establishing age and sex specific 
reference values,  this paper sets out some thought provoking insights into alternative 
remodelling routes which occur in the presence of complex cardiovascular risk factors when 
gender is considered. The authors acknowledge that there are limitations to the study; 
microcirculatory endothelial function was not examined, which itself is strongly associated 
with cardiovascular events  but not necessarily due to changes in media to lumen ratio [9], 
furthermore, any change in reference values due to ethnicity is likely to require further 
studies [1]. 
The clinical impact of these findings could be phenomenal. However, the translation of 
these measures is limited by the very nature in which they are taken; the invasiveness 
required precludes this from being a valuable clinical resource and a way of looking closely 
at the microcirculation in vivo is needed urgently. Maybe assessing retinal arteries under 
standardised conditions is the way forward [10], however until a prognostic value of non-
invasive measures of microvascular structure is made, progression is somewhat limited [11]. 
What can be taken from this study is that we cannot see patients as being the same: 
normality cannot be assumed. In an era where we are moving progressively towards 
personalised medicine, the Bruno group is making small, yet important steps, in 
personalising cardiovascular medicine for improved outcomes and patient care. We wait 
with keen anticipation for their next studies in this field. 
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